Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07097142 · ClinicalTrials.gov registry record · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
A Phase 3 study of Stage II Bladder Cancer AJCC v8 and Stage IIIA Bladder Cancer AJCC v8, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 486
- Enrollment target
- 20
- Study locations
NCT07097142 is a Phase 3 study of Stage II Bladder Cancer AJCC v8 and Stage IIIA Bladder Cancer AJCC v8 that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 486 participants, above the 230-participant average among 6 other Stage II Bladder Cancer AJCC v8 trials with a reported enrollment target (111% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT07097142, a Phase 3 study of Stage II Bladder Cancer AJCC v8 and Stage IIIA Bladder Cancer AJCC v8, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 486 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients with muscle invasive bladder cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a short period of time. Ultra-hypofractionated radiation therapy delivers radiation over an even shorter period of time than hypofractionated radiation therapy. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Chemotherapy drugs, such as mitomycin-C and 5-fluorouracil (5-FU), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ultra-hypofractionated radiation may be equally effective as hypofractionated therapy for patients with muscle invasive bladder cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Cisplatin
- DRUG Fluorouracil
- DRUG Gemcitabine
Study Locations (20)
Delaware
- Beebe Medical Center - Lewes
- Beebe South Coastal Health Campus - Millville
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Beebe Health Campus - Rehoboth Beach
- Christiana Care Health System-Wilmington Hospital - Wilmington
Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- UM Sylvester Comprehensive Cancer Center at Doral - Doral
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- Miami Cancer Institute - Miami
- UM Sylvester Comprehensive Cancer Center at Kendall - Miami
- UM Sylvester Comprehensive Cancer Center at Plantation - Plantation
California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- UC San Diego Moores Cancer Center - La Jolla
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Comprehensive Cancer Center - Sacramento
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Georgia
- Grady Health System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2030-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07097142
The ClinicalTrials.gov registry entry for NCT07097142 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 486 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 6 other Stage II Bladder Cancer AJCC v8 trials with a reported enrollment target (111% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage II Bladder Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07097142 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Delaware, Florida, California.
Frequently Asked Questions
What is clinical trial NCT07097142 about?
NCT07097142 is a clinical study titled "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study". This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients ...
What is the current status of trial NCT07097142?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 486 participants. The study started on 2026-05-11. Estimated completion is 2030-05-31.
What conditions does trial NCT07097142 study?
This clinical trial studies the following conditions: Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Urothelial Carcinoma.
What interventions are being tested in trial NCT07097142?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Cisplatin (DRUG), Fluorouracil (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT07097142?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07097142 being conducted?
This trial has 20 study locations across Arkansas, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Bladder Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
RECRUITING · Phase 2
-
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
RECRUITING
-
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RECRUITING · Phase 2
-
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Stage II Bladder Cancer AJCC v8
All registered trials for this condition
Stage IIIA Bladder Cancer AJCC v8
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.